Saturday, October 24, 2009 5:50:49 PM
I can’t help but wonder about any possible role of the USAMRID resources being assigned the task of: 1.) expedite further H1N1 testing of the hemopurifier and 2.) helping to consult on a hastily arranged emergency manufacture of H1N1/hemopurifiers.
My thoughts are perhaps wildly speculative here, but I do recall that USAMRID resources were applied to help Northrup Grumman (NOC) and Cepheid (CPHD) to move into high volume production of Anthrax Testing equipment for the US Postal Service around 2002-2003.
USAMRID, which is already working with AEMD, has lots of resources. I would think that some of the folks within USAMRID might be asking the same questions about H1N1 & the Hemopurifier. ???
Thanks to all who have posted helpful info here.
BBarry
My thoughts are perhaps wildly speculative here, but I do recall that USAMRID resources were applied to help Northrup Grumman (NOC) and Cepheid (CPHD) to move into high volume production of Anthrax Testing equipment for the US Postal Service around 2002-2003.
USAMRID, which is already working with AEMD, has lots of resources. I would think that some of the folks within USAMRID might be asking the same questions about H1N1 & the Hemopurifier. ???
Thanks to all who have posted helpful info here.
BBarry
Recent AEMD News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 11:27:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 11:27:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 11:27:18 PM
- Advancements in Novel Immunotherapeutics in The Oncology Battle • Newsfile • 03/24/2026 02:30:00 PM
- Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review • PR Newswire (US) • 03/24/2026 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/17/2026 01:15:09 PM
- Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing • GlobeNewswire Inc. • 03/13/2026 12:35:00 PM
- Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities • PR Newswire (US) • 03/12/2026 12:01:00 PM
- Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th • GlobeNewswire Inc. • 03/10/2026 02:21:44 PM
- Aethlon Medical to Present at the Life Sciences Investor Forum on March 12th • GlobeNewswire Inc. • 03/06/2026 01:35:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2026 09:15:32 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 02/18/2026 02:54:05 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/18/2026 01:22:47 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/12/2026 10:10:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2026 09:15:44 PM
- Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update • PR Newswire (US) • 02/12/2026 09:15:00 PM
- Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026 • PR Newswire (US) • 02/04/2026 01:01:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/27/2026 09:15:36 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/27/2026 09:15:26 PM
